deltatrials
Completed PHASE2 NCT00039104

Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer

A Phase II, Open-Label, Randomized Trial of Zoledronic Acid (Zometa™) and BMS-275291 (NSC#713763) in Patients With Hormone Refractory Prostate Cancer

Sponsor: National Cancer Institute (NCI)

Conditions Adenocarcinoma of the Prostate Recurrent Prostate Cancer Stage IV Prostate Cancer
Interventions laboratory biomarker analysis rebimastat zoledronic acid
Updated 6 times since 2017 Last updated: Jun 4, 2013 Started: Apr 30, 2002 Primary completion: Jan 31, 2005

Listed as NCT00039104, this PHASE2 trial focuses on Adenocarcinoma of the Prostate and Recurrent Prostate Cancer and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 6 times since 2002, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Apr 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Rochester, United States